Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II double-blind placebo-controlled trial of romiplostim for chemotherapy-induced thrombocytopenia prophylaxis in relapsed ovarian cancer
2013-002564-69Phase 2Terminated
- Sponsor
- GMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH
- Start
- Jan 2014
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chemotherapy-induced thrombocytopenia (CIT) comparing Romiplostim + chemotherapy with Placebo + chemotherapy (2 arms). Started Jan 2014; status: terminated.
02
Drugs
romiplostim
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on 2013-002564-69.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002564-69.